Clene (CLNN) Projected to Post Earnings on Thursday

Clene (NASDAQ:CLNN) will likely be issuing its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Clene to announce earnings of ($0.46) per share and revenue of $0.07 million for the quarter. Investors are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 7:00 AM ET.

Clene (NASDAQ:CLNN) last issued its earnings results on Wednesday, November 4th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.50. The business had revenue of $0.06 million during the quarter, compared to analysts’ expectations of $0.07 million. On average, analysts expect Clene to post ($1.05) EPS for the current fiscal year and ($1.17) EPS for the next fiscal year.

Clene Price Performance

NASDAQ:CLNN opened at $4.41 on Wednesday. The firm has a market capitalization of $63.50 million, a PE ratio of -1.70 and a beta of 1.04. Clene has a 12 month low of $3.02 and a 12 month high of $10.84. The business’s 50-day moving average is $3.90 and its two-hundred day moving average is $5.12.

Analysts Set New Price Targets

A number of research firms have recently issued reports on CLNN. Wall Street Zen upgraded shares of Clene from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright reiterated a “buy” rating on shares of Clene in a research report on Monday, October 19th. Finally, Weiss Ratings downgraded shares of Clene from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, October 27th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Clene currently has an average rating of “Moderate Buy” and a consensus target price of $34.00.

About Clene

Clene Inc. is a clinical-stage biopharmaceutical company developing nanotherapeutic treatments for neurodegenerative diseases. The company’s lead product candidate, CNM-Au8, is an investigational oral suspension containing catalytically active gold nanocrystals designed to support cellular energy production and reduce oxidative stress, with the goal of protecting and improving the function of nerve cells. Clene has studied CNM-Au8 in conditions including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), and has also investigated its potential applications in other neurodegenerative disorders.